Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Cómo citar

Aina Oliver‐Caldés, & Verónica González‐Calle, & Valentín Cabañas, & Marta Español‐Rego, & Paula Rodríguez‐Otero, & Juan Luís Reguera, & Lucía López‐Corral, & Beatriz Martín-Antonio, & Aintzane Zabaleta, & Susana Inogés, & Sara Varea, & Laura Rosiñol, & Ascensión López-Dı́az de Cerio, & Natalia Tovar, & Raquel Jiménez, & Miriam López-Parra, & Luis Gerardo Rodríguez‐Lobato, & Andrés Sánchez‐Salinas, & Eulàlia Olesti, & María Calvo‐Orteu, & Julio Delgado, & Josè Antonio Pérez-Simón, & Bruno Paiva, & Felipe Prósper, & Joaquín Sáez‐Peñataro, & Manel Juan, & José M. Moraleda, & María‐Victoria Mateos, & Mariona Pascal, & Álvaro Urbano-Ispizúa, & Carlos Fernández de Larrea (2023). Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. https://doi.org/10.1016/s1470-2045(23)00222-x